388 related articles for article (PubMed ID: 14529064)
1. Levetiracetam: a new therapeutic option for refractory epilepsy.
Pinto A; Sander JW
Int J Clin Pract; 2003 Sep; 57(7):616-21. PubMed ID: 14529064
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of levetiracetam: a review of three pivotal clinical trials.
Privitera M
Epilepsia; 2001; 42 Suppl 4():31-5. PubMed ID: 11564123
[TBL] [Abstract][Full Text] [Related]
3. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy.
Steinhoff BJ; Somerville ER; Van Paesschen W; Ryvlin P; Schelstraete I
Epilepsy Res; 2007 Aug; 76(1):6-14. PubMed ID: 17681453
[TBL] [Abstract][Full Text] [Related]
4. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial.
Peltola J; Coetzee C; Jiménez F; Litovchenko T; Ramaratnam S; Zaslavaskiy L; Lu ZS; Sykes DM;
Epilepsia; 2009 Mar; 50(3):406-14. PubMed ID: 19317886
[TBL] [Abstract][Full Text] [Related]
5. Levetiracetam for people with mental retardation and refractory epilepsy.
Kelly K; Stephen LJ; Brodie MJ
Epilepsy Behav; 2004 Dec; 5(6):878-83. PubMed ID: 15582836
[TBL] [Abstract][Full Text] [Related]
6. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures.
Wu XY; Hong Z; Wu X; Wu LW; Wang XF; Zhou D; Zhao ZX; Lv CZ
Epilepsia; 2009 Mar; 50(3):398-405. PubMed ID: 18657175
[TBL] [Abstract][Full Text] [Related]
7. Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center.
Bootsma HP; Ricker L; Diepman L; Gehring J; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M; Aldenkamp AP
Epilepsy Behav; 2007 Mar; 10(2):296-303. PubMed ID: 17317325
[TBL] [Abstract][Full Text] [Related]
8. Long-term use of Levetiracetam in patients with severe childhood-onset epilepsy.
von Stuelpnagel C; Holthausen H; Kluger G
Eur J Paediatr Neurol; 2007 Nov; 11(6):341-5. PubMed ID: 17442601
[TBL] [Abstract][Full Text] [Related]
9. Preliminary efficacy of levetiracetam in monotherapy.
Ben-Menachem E
Epileptic Disord; 2003 May; 5 Suppl 1():S51-5. PubMed ID: 12915342
[TBL] [Abstract][Full Text] [Related]
10. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
Abou-Khalil B; Hemdal P; Privitera MD
Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
[TBL] [Abstract][Full Text] [Related]
11. Monotherapy for partial epilepsy: focus on levetiracetam.
Gambardella A; Labate A; Colosimo E; Ambrosio R; Quattrone A
Neuropsychiatr Dis Treat; 2008 Feb; 4(1):33-8. PubMed ID: 18728811
[TBL] [Abstract][Full Text] [Related]
12. Measurement of seizure freedom in adjunctive therapy studies in refractory partial epilepsy: the levetiracetam experience.
Leppik I; De Rue K; Edrich P; Perucca E
Epileptic Disord; 2006 Jun; 8(2):118-30. PubMed ID: 16793573
[TBL] [Abstract][Full Text] [Related]
13. Use of levetiracetam in hospitalized patients.
Falip M; Carreño M; Amaro S; Donaire A; Delgado R; Toledo M; Maestro I
Epilepsia; 2006 Dec; 47(12):2186-8. PubMed ID: 17201722
[TBL] [Abstract][Full Text] [Related]
14. Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures.
Piña-Garza JE; Nordli DR; Rating D; Yang H; Schiemann-Delgado J; Duncan B;
Epilepsia; 2009 May; 50(5):1141-9. PubMed ID: 19243423
[TBL] [Abstract][Full Text] [Related]
15. Randomized-controlled trials of levetiracetam as an adjunctive therapy in epilepsy of multiple seizure types.
Fang Y; Wu X; Xu L; Tang X; Wang J; Zhu G; Hong Z
J Clin Neurosci; 2014 Jan; 21(1):55-62. PubMed ID: 24231559
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of levetiracetam (3,000 mg/Day) as an adjunctive therapy in Chinese patients with refractory partial seizures.
Xiao Z; Li JM; Wang XF; Xiao F; Xi ZQ; Lv Y; Sun HB
Eur Neurol; 2009; 61(4):233-9. PubMed ID: 19176965
[TBL] [Abstract][Full Text] [Related]
17. Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam.
Kaminski RM; Matagne A; Patsalos PN; Klitgaard H
Epilepsia; 2009 Mar; 50(3):387-97. PubMed ID: 18627416
[TBL] [Abstract][Full Text] [Related]
18. Onset of action of levetiracetam: a RCT trial using therapeutic intensive seizure analysis (TISA).
Stefan H; Wang-Tilz Y; Pauli E; Dennhöfer S; Genow A; Kerling F; Lorber B; Fraunberger B; Halboni P; Koebnick C; Gefeller O; Tilz C
Epilepsia; 2006 Mar; 47(3):516-22. PubMed ID: 16529615
[TBL] [Abstract][Full Text] [Related]
19. Safety profile of levetiracetam.
Arroyo S; Crawford P
Epileptic Disord; 2003 May; 5 Suppl 1():S57-63. PubMed ID: 12915343
[TBL] [Abstract][Full Text] [Related]
20. Clinical predictors in patients with refractory epilepsy exposed to levetiracetam: a single-center study.
Peltola J; Peltola M; Auvinen A; Keränen T; Liimatainen S; Kharazmi E; Fallah M
Acta Neurol Scand; 2008 May; 117(5):332-6. PubMed ID: 18081915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
